“Growing Adoption of Combination Therapies”
A key trend in the hepatic encephalopathy treatment market is the growing adoption of combination therapies to enhance treatment efficacy. Combining antibiotics such as rifaximin with lactulose has become a standard approach to reducing ammonia levels in patients, improving clinical outcomes. Recent advancements include the development of soluble solid dispersion (SSD) formulations of rifaximin, currently in Phase III clinical trials, which aim to improve drug bioavailability and patient compliance. This trend addresses the limitations of monotherapy, such as suboptimal response rates and recurrence of symptoms. Moreover, healthcare providers are increasingly using combination regimens in tandem with dietary modifications and ammonia-lowering agents such as L-ornithine-L-aspartate for comprehensive management. For instance, Bausch Health’s ongoing research into enhanced rifaximin formulations exemplifies the industry's focus on optimizing existing treatments. As awareness of hepatic encephalopathy grows, the demand for such innovative therapies continues to drive market expansion, particularly in regions with rising liver disease prevalence.
